Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Marzeptacog alfa - GC Biopharma

Next Previous
Drug Profile

Marzeptacog alfa - GC Biopharma

Alternative Names: CB 813; CB 813d; MarzAA; Marzeptacog alfa (activated); Marzeptacog alpha; PF-05280602; PF-5280602; Recombinant Factor VIIa variant (813d); SQ MarzAA; SQ marzeptacog alfa (activated)

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Catalyst Biosciences
  • Class Antihaemorrhagics; Blood coagulation factors; Peptide hydrolases; Recombinant proteins
  • Mechanism of Action Factor VIIa replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia B; Haemophilia A; Factor VII deficiency
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Factor VII deficiency; Haemophilia; Haemophilia A; Surgical blood loss; Thrombasthenia

Most Recent Events

  • 30 Oct 2023 GNI has merged with Catalyst Biosciences to form Gyre Therapeutics
  • 27 Feb 2023 GC Biopharma acquires Marzeptacog alfa from Catalyst Biosciences
  • 21 Dec 2021 Catalyst Biosciences terminates a phase I/II trial in Factor VII deficiency, Thrombastenia and Haemophilia A in USA (SC) owing to company's decision (NCT04548791)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top